{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:15:40Z","timestamp":1775520940861,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ejmech.2021.113338","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:50:34Z","timestamp":1615510234000},"page":"113338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma"],"prefix":"10.1016","volume":"217","author":[{"given":"Kunal","family":"Nepali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7524-7740","authenticated-orcid":false,"given":"Tsung-I","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7204-4681","authenticated-orcid":false,"given":"Chien-Ming","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Lun","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-8711","authenticated-orcid":false,"given":"Mei-Jung","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Cheng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony Eight","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5124-0643","authenticated-orcid":false,"given":"Jian-Ying","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3775-6405","authenticated-orcid":false,"given":"Jing-Ping","family":"Liou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113338_bib1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/bs.ircmb.2017.03.002","article-title":"MicroRNAs as multifaceted players in glioblastoma multiforme","volume":"333","author":"Mercatelli","year":"2017","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.113338_bib2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant gliomas in adults","volume":"359","author":"Wen","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2021.113338_bib3","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ph6121475","article-title":"Glioblastoma multiforme therapy and mechanisms of resistance","volume":"6","author":"Ramirez","year":"2013","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2021.113338_bib4","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1200\/JCO.2007.11.8554","article-title":"Chemoradiotherapy in malignant glioma: standard of care and future directions","volume":"25","author":"Stupp","year":"2007","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2021.113338_bib5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2021.113338_bib6","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.biopha.2017.05.125","article-title":"Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: a review","volume":"92","author":"Anjum","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2021.113338_bib7","first-page":"241","article-title":"Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma","volume":"37","author":"Meng","year":"2018","journal-title":"J.\u00a0Exp. Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113338_bib8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.addr.2018.10.013","article-title":"Approaches to physical stimulation of metallic nanoparticles for glioblastoma treatment","volume":"138","author":"Pinel","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2021.113338_bib9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/neuonc\/nox142","article-title":"Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization","volume":"20","author":"Garnier","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2021.113338_bib10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2021.113338_bib11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2176\/nmc.ra.2018-0141","article-title":"Potential strategies overcoming the temozolomide resistance for glioblastoma","volume":"58","author":"Jiapaer","year":"2018","journal-title":"Neurol. Med.-Chir."},{"key":"10.1016\/j.ejmech.2021.113338_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140131","article-title":"Temozolomide resistance in glioblastoma cell lines: implication of MGMT, MMR, P-Glycoprotein and CD133 expression","volume":"10","author":"Perazzoli","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2021.113338_bib13","first-page":"5905","article-title":"Sp1 acetylation associates with stemness characteristics in temozolomide-resistant glioblastoma [abstract]","volume":"vol. 78","author":"Chuang","year":"2018"},{"key":"10.1016\/j.ejmech.2021.113338_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.med.58.062105.204854","article-title":"Cancer stem cells: models and concepts","volume":"58","author":"Dalerba","year":"2007","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejmech.2021.113338_bib15","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of human brain tumour initiating cells","volume":"432","author":"Singh","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113338_bib16","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113338_bib17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","article-title":"Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance","volume":"20","author":"Liau","year":"2017","journal-title":"Cell stem cell"},{"key":"10.1016\/j.ejmech.2021.113338_bib18","first-page":"271","article-title":"Cancer stem cells and chemoresistance in glioblastoma multiform: a review article","volume":"10","author":"Safari","year":"2015","journal-title":"J.\u00a0Stem Cell."},{"key":"10.1016\/j.ejmech.2021.113338_bib19a","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1367-5931(97)80066-X","article-title":"Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs","volume":"300","author":"Hassig","year":"1997","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2021.113338_bib19b","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2174\/187152009788679976","article-title":"Histone deacetylase inhibitors: design, structure activity relationships and therapeutic implication implications for cancer","volume":"9","author":"Marson","year":"2009","journal-title":"Anti Canc. Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113338_bib19c","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1367-5931(97)80066-X","article-title":"Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs","volume":"1","author":"Hassig","year":"1997","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2021.113338_bib19d","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/acs.jmedchem.7b01404","article-title":"(N-Hydroxycarbonylbenylamino)quinolines as selective histone deacetylase 6 inhibitors suppress growth of multiple myeloma in\u00a0vitro and in\u00a0vivo","volume":"61","author":"Lee","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113338_bib19e","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatment for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat. Rev. Canc."},{"issue":"4","key":"10.1016\/j.ejmech.2021.113338_bib20a","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/cas.12379","article-title":"Epigenetic dysregulation in glioma","volume":"105","author":"Kondo","year":"2014","journal-title":"Canc. Sci."},{"key":"10.1016\/j.ejmech.2021.113338_bib20b","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.molonc.2012.10.006","article-title":"Epigenetic alterations involved in cancer stem cell reprogramming","volume":"6","author":"Mu\u00f1oz","year":"2012","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2021.113338_bib20c","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-018-0598-5","article-title":"Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells","volume":"11","author":"Was","year":"2019","journal-title":"Clin. Epigenet."},{"issue":"5","key":"10.1016\/j.ejmech.2021.113338_bib21a","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127058","article-title":"The HDAC inhibitors Scriptaid and LBH589 combined with the oncolytic virus Delta24-RGD exert enhanced anti-tumor efficacy in patient-derived glioblastoma cells","volume":"10","author":"Berghauser Pont","year":"2015","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.ejmech.2021.113338_bib21b","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.molonc.2015.12.014","article-title":"Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma","volume":"10","author":"Rasmussen","year":"2016","journal-title":"Mol. Oncol"},{"key":"10.1016\/j.ejmech.2021.113338_bib18C","doi-asserted-by":"crossref","first-page":"18577","DOI":"10.18632\/oncotarget.14612","article-title":"Advances in epigenetic glioblastomatherapy","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2021.113338_bib22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12929-016-0296-6","article-title":"Suberoylanilide hydroxamic acid represses glioma stem-like cells","volume":"23","author":"Hsu","year":"2016","journal-title":"J.\u00a0Biomed. Science"},{"key":"10.1016\/j.ejmech.2021.113338_bib23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41419-020-2586-x","article-title":"Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma","volume":"11","author":"Iriarte","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2021.113338_bib24","first-page":"1797","article-title":"An inhibitor of HDAC6, enhances temozolomide-induced apoptosis and reverses the malignant phenotype of glioblastoma cells","volume":"54","author":"Urdiciain","year":"2019","journal-title":"Int. J. Onc."},{"key":"10.1016\/j.ejmech.2021.113338_bib25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1515\/med-2018-0034","article-title":"Growth suppression of glioma cells using HDAC6 inhibitor, tubacin","volume":"13","author":"Yin","year":"2018","journal-title":"Open Med."},{"key":"10.1016\/j.ejmech.2021.113338_bib26","doi-asserted-by":"crossref","first-page":"iii53","DOI":"10.1093\/neuonc\/noz126.192","article-title":"Discovery of a new HDAC6 inhibitor for the treatment of glioblastoma","volume":"21","author":"Auzmendi-Iriarte","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2021.113338_bib27a","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11060-011-0717-z","article-title":"Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma","volume":"107","author":"Drappatz","year":"2012","journal-title":"J.\u00a0Neuro Oncol."},{"key":"10.1016\/j.ejmech.2021.113338_bib27b","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/neuonc\/nor198","article-title":"Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study","volume":"14","author":"Friday","year":"2012","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2021.113338_bib27c","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2008.19.0694","article-title":"Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study","volume":"27","author":"Galanis","year":"2009","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2021.113338_bib27d","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/neuonc\/nou350","article-title":"Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma","volume":"17","author":"Lee","year":"2015","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2021.113338_bib28","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.2147\/DDDT.S79592","article-title":"Drug delivery strategies to enhance the permeability of the blood\u2013brain barrier for treatment of glioma","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2021.113338_bib29a","first-page":"402","article-title":"Memantine induces apoptosis and inhibits cell cycle progression in LNCaP prostate cancer cells","volume":"109","author":"Albayrak","year":"2017","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2021.113338_bib29b","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ejps.2017.08.030","article-title":"Memantine-derived drugs as potential antitumor agents for the treatment of Glioblastoma","volume":"109","author":"Cacciatorea","year":"2017","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2021.113338_bib30","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.2174\/0929867323666160525114026","article-title":"Adamantane - a lead structure for drugs in clinical practice)","volume":"23","author":"Spilovska","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113338_bib31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.canlet.2016.06.001","article-title":"HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma","volume":"28","author":"Wang","year":"2016","journal-title":"Canc. Lett."},{"key":"10.1016\/j.ejmech.2021.113338_bib32a","doi-asserted-by":"crossref","first-page":"19571","DOI":"10.1039\/C9RA02985K","article-title":"Next-generation of selective histone deacetylase inhibitors","volume":"9","author":"Yang","year":"2019","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2021.113338_bib32b","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","article-title":"Zinc binding groups for histone deacetylase inhibitors","volume":"33","author":"Zhang","year":"2018","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113338_bib33","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.redox.2017.08.005","article-title":"Specificity protein 1 modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O(6)-methylguanine-DNA methyltransferase","volume":"13","author":"Chang","year":"2017","journal-title":"Redox Biol"},{"key":"10.1016\/j.ejmech.2021.113338_bib34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12929-016-0296-6","article-title":"Suberoylanilide hydroxamic acid represses glioma stem-like cells","volume":"23","author":"Hsu","year":"2016","journal-title":"J.\u00a0Biomed. Sc."},{"key":"10.1016\/j.ejmech.2021.113338_bib35","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.freeradbiomed.2011.10.001","article-title":"Hydrogen peroxide induces Sp1 methylation and thereby suppresses cyclin B1 via recruitment of Suv39H1 and HDAC1 in cancer cells","volume":"51","author":"Chuang","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2021.113338_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2021.113338_bib37","author":"LeadIT"},{"key":"10.1016\/j.ejmech.2021.113338_bib38","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/j.1471-4159.1992.tb10055.x","article-title":"Drug transfer across the blood-brain barrier: correlation between in\u00a0vitro and in\u00a0vivo models","volume":"58","author":"Dehouck","year":"1992","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2021.113338_bib39","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.redox.2017.08.005","article-title":"Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O(6)-methylguanine-DNA methyltransferase","volume":"13","author":"Chang","year":"2017","journal-title":"Redox Biol"},{"key":"10.1016\/j.ejmech.2021.113338_bib40","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/neuonc\/noaa103","article-title":"Increased activation of HDAC1\/2\/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma","volume":"22","author":"Yang","year":"2020","journal-title":"Neuro Oncol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421001872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421001872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:26:30Z","timestamp":1759328790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421001872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":53,"alternative-id":["S0223523421001872"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113338","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113338","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113338"}}